Cancer burden in the year 2000. The global picture. by Parkin, DM et al.
Mller, H; Fairley, L; Coupland, V; Okello, C; Green, M; Forman, D;
Mller, B; Bray, F (2007) The future burden of cancer in England:
incidence and numbers of new patients in 2020. British journal of
cancer, 96 (9). pp. 1484-8. ISSN 0007-0920
Downloaded from: http://researchonline.lshtm.ac.uk/10047/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/The future burden of cancer in England: incidence and numbers of
new patients in 2020
H Møller*,1, L Fairley
2, V Coupland
1, C Okello
1, M Green
3, D Forman
2, B Møller
4 and F Bray
4
1King’s College London, Thames Cancer Registry, 42 Weston Street, London SE1 3QD, UK;
2Northern and Yorkshire Cancer Registry and Information
Service, Arthington House, Cookridge Hospital, Leeds LS16 6QB, UK;
3Standards and Quality Analytical Team, Department of Health, Area 403,
Wellington House, 135-155 Waterloo Road, London SE1 8UG, UK;
4Cancer Registry of Norway, Montebello, N-0310 Oslo, Norway
We estimated the future cancer incidence rates and the future numbers of cancer cases in England up to 2020 using cancer
registration data for 1974–2003, and the official population projections from ONS up to 2023. Data were analysed using an age-
period-cohort model as developed for the Nordic countries. We predict that for all cancers combined there will be relatively little
change in age-standardised incidence rates in 2020. The number of new cancer cases per year in England is, however, predicted to
increase by 33%, from 224000 in 2001 to 299000 cases in 2020. This increase is mainly due to the anticipated effects of population
growth and ageing; cancer patients in 2020 will be older than today’s cancer population.
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We can quantify the future burden of cancer from two different
perspectives. Firstly, age-standardised rates describe the occurrence
of cancer on a per capita basis, taking account of changes in age
composition and size of the population (Parkin, 2006). Secondly,
from the point of view of cancer care and cancer services provision,
the burden of cancer is more usefully measured as the total number
of persons with cancer who require diagnostic, therapeutic,
supportive or palliative services (Bray and Møller, 2006).
Several large studies have forecast future cancer rates and
numbers, using a variety of statistical methods (Møller et al, 2002;
New Zealand Ministry of Health, 2002; Scottish Executive, 2004;
Clements et al, 2005). The most common methods relate incidence
to the three interdependent time dimensions of age, calendar
period and generation. When cancer rates have changed linearly in
recent periods and in consecutive generations, it is reasonable to
expect the change to continue, at least to some degree and for some
time. When particularly low or high rates are observed in a recent
generation at a young age, it may be reasonable to assume that this
generation will be subject to similar rates when they become older.
Future changes are only predictable if they are linear extensions of
past trends; otherwise, future period effects are not predictable
from past rates. This is a major source of uncertainty in cancer
forecasts and is the main reason why many predictions turn out to
be too low or too high.
SUBJECTS AND METHODS
For this analysis of the future cancer rates and numbers of cancer
cases in England, we have used a method of estimation that was
developed in a comprehensive and systematic analysis of cancer
trends in the Nordic countries (Møller et al, 2002, 2003). Møller
and co-workers used the long data series in the Nordic countries to
develop a large number of predictions of present rates as would
have been forecast 20 years ago, and compared the predicted rates
with those actually observed, identifying a set of analysis options
that tended to give the most accurate predictions. Our analysis of
the English data adopts the Nordic method of estimation and the
standard set of recommendations with very few modifications. The
analysis makes no assumption about changes in exposure to risk
factors, but relies entirely on the extrapolation of the recorded
rates in the past.
Data on cancer incidence counts and corresponding population
denominators in England were obtained from the Office for
National Statistics. The data were aggregated into 5-year periods
(1974–1978, y 1999–2003) and 5-year age groups (0–4, 5–9, y
80–84, 85þ) by sex. Cancers were categorised into 21 commonly
used types on the basis of ICD9 and ICD10 codes; remaining types
were categorised as ‘other sites’ and analysed as a separate group
when summing up to the figures for all cancers combined.
Population figures consisted of forecasts for four future 5-year
periods (2004–2008, 2009–2013, 2014–2018, 2019–2023) in 5-year
age groups by sex. As an approximation, these 5-year periods were
used to represent the single years 2005, 2010, 2015 and 2020,
respectively. The predicted cancer burden was measured by the
numbers of cancer cases in future calendar periods and calculated
by first projecting the observed cancer incidence trends, then
multiplying these predicted incidence rates by the forecast
populations in these periods.
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period and birth cohort, with the central value of the latter
calculated by subtracting the midpoint of each age category from
the midpoint of the period. A recent approach to projecting
incidence rates (Møller et al, 2002) was adapted for most of the
cancer sites, based on a standard age-period-cohort model
(Osmond, 1985), but with some modifications which have been
shown empirically to improve the predictions (Møller et al, 2003).
The multiplicative relationship between incidence and the covari-
ates in the standard model produces predictions in which the rates
change exponentially with time. The first modification was to use a
power link function instead of the default logarithmic link function
in Poisson regression as this has been demonstrated to level off the
exponential growth rates. The model can be written as Rap ¼
ðAa þ D   p þ Pp þ CcÞ
5; where Rap is the incidence rate in age
group a in calendar period p, Aa is the age component for age
group a, D is the common drift parameter which summarises the
linear component of the trend, which cannot be attributed to either
period or cohort (Clayton and Schifflers, 1987). Pp is the nonlinear
period component of period p and Cc is the nonlinear cohort
component of cohort c. The linear component D and the nonlinear
cohort effects were projected. To allow for a damping of the impact
of current trends in the future time periods, a gradual reduction in
the drift parameter of 25, 50 and 75% in the second, third and
fourth 5-year period, respectively, was used. Misleading predictions
can occur if there is a recent sharp change in the trends, and the
average increase over the entire observation period is projected. To
improve accuracy, the trend in the most recent 10 years was used as
the drift component to be projected in situations where the rates
had statistically significant curvature in the prediction base.
For cancers of the prostate and bladder, future rates were not
based on extrapolation of past trends, but by assuming that the
rates would remain unchanged from those in the most recent
period, 1999–2003. Extrapolation of trends could not be justified,
as recent artefactual changes were considered unlikely to continue
(see Discussion).
We summarised the results using the cumulative risk to age 75
years, the age-standardised incidence rates using the European
standard population (Day, 1987), and the future numbers of new
cancer cases (in thousands per year). We considered the changes
in these parameters, both in absolute and in relative terms. The
percentage change in the annual number of cases from 2001 to
2020 was divided into one part due to increased risk of being
diagnosed with cancer, and another due to changes in the
population size and age distribution (Møller et al, 2002). The
prediction package NORDPRED written in R is available online
(Nordpred, 2006).
RESULTS
Considered overall, the age-standardised incidence rates of all
cancers combined (excluding non-melanoma skin cancer) are
predicted to decrease in males and increase slightly in females
(Figure 1). Figure 2 shows the age-standardised incidence rates for
different cancers. The blue lines denote the rates in men and the
red lines the rates in women. The empirical rates up to 2003 are
shown with a thicker line than the predicted rates from 2004 to
2021. The Y-axis is logarithmic and identical in all the individual
diagrams. The analysis predicts increasing rates in several cancers:
oral cavity and pharynx, melanoma, testis (all with increases of
30–40%) and non-Hodgkin’s lymphoma (10–20% increase).
Decreasing rates are predicted for cancers of the stomach, colon,
lung, cervix and brain (decreases of 10–25%).
Table 1 shows the forecast change in numbers of cancer cases
from 2001 to 2020. In contrast to the predicted future incidence
rates, the numbers of cancer cases in the English population are
predicted to increase very substantially from around 224000 in
2001 to around 299000 in 2020. This is an increase of 33% (36% in
males; 30% in females). The main reason is the increasing
population, especially of middle-aged and old people.
Table 1 also shows the change in numbers of different cancers
and breaks down the increases into the contribution from change
in incidence and change in the population at risk. For most
cancers, the effect of demography is stronger than the effect of
changing incidence rates. Notable exceptions are oral and
pharyngeal cancer, melanoma, testis cancer and Hodgkin’s
lymphoma where the changes in incidence are greater than the
change in population. For cancers of the breast, uterine corpus and
kidney (in females), the contributions of incidence rate and
population are of similar magnitude.
DISCUSSION
Among systematic studies of national and international cancer
incidence trends (Hakulinen et al, 1986; Coleman et al, 1993;
Quinn et al, 2001; Scottish Executive, 2004), the general pattern in
past decades has been an increase in the age-standardised
incidence rates of all cancers combined. With respect to cancer
prevention, our study has shown that a turning point may have
been reached or is soon to be reached, and that cancer rates in
England are now decreasing in males and are predicted to start
decreasing from 2015 in females. The single most important factor
in this stabilisation is probably the reduction in smoking
prevalence. Cancer will continue to affect the lives of a great
many people in England, emphasising the continued need for
primary prevention. Although preventive interventions may have a
material impact on particular types of cancer with known, strong
and preventable causes (such as lung cancer, oral cancer and
cervix cancer), the general impact of primary prevention on the
total age-adjusted cancer incidence in the next decades will
probably be relatively small unless new and powerful preventive
measures are discovered and put into practice.
The predicted growth in the total annual number of cancer cases
in the population represents an important gradual increase in the
workload and resource requirements for cancer care services in the
coming years. Much of the predicted growth will take place in the
older age groups, for which cancer services will need to be
developed (Haward, 2006). Future cancer services provision
should give consideration to the special circumstances of this
group, including increased surgical mortality, toxicity of chemo-
therapy, treatment-related complications, general comorbidity,
and special needs for supportive and palliative care (Edwards et al,
2002; Balducci and Ershler, 2005). In parallel with the increasing
number of cancer patients, it is likely that patients’ expectations,
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Figure 1 Trends in age-standardised (European standard population)
incidence rates of all cancers combined (excluding non-melanoma skin
cancer) up to 2020. Rates in males in blue; rates in females in red.
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Figure 2 Trends in age-standardised (European standard population) incidence rates of different cancers and predictions up to 2020. Rates in males in
blue; rates in females in red.
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yTable 1 Recorded cancer incidence in males and females in England 2001, predicted cancer incidence around 2020 and the corresponding percentage change in incidence, decomposed into changing risk
and demographic components
Males Females
ICD-10 code Cancer type
Number of
cancer cases
in 2001
a
Number of
cancer cases
in 2020
b
Change
overall (%)
c
Change due
to change in
risk (%)
d
Change due
to change in
population
(%)
e
Number of
cancer cases
in 2001
a
Number of
cancer cases
in 2020
b
Change
overall (%)
c
Change due
to change in
risk (%)
d
Change due
to change in
population
(%)
e
C00-C14 Lip, mouth,
pharynx
2624 4584 75 43 32 1458 2290 57 34 23
C15 Oesophagus 3771 5974 58 15 43 2293 2770 21  62 6
C16 Stomach 4780 5046 6  42 47 2649 2468  7  33 26
C18 Colon 8872 11692 32  15 46 8746 9786 12  14 26
C19–C21 Rectum 6468 9842 52 10 42 4503 6090 35 10 25
C25 Pancreas 2852 4198 47 2 45 3022 3683 22  42 6
C33–C34 Lung 18495 18519 0  45 45 12004 13600 13  12 26
C43 Melanoma 2629 4942 88 58 30 3377 5608 66 49 17
C50 Breast ————— 3 4 6 3 6 4 9 7 4 3 4 42 2 2 1
C53 Cervix uteri —————2420 2123  12  24 12
C54 Corpus uteri —————4684 7149 53 27 25
C56–C57 Ovary —————5612 6933 24 1 23
C61 Prostate
f 24717 36703 48 0 48 — — — — —
C62 Testis 1600 2332 46 39 7 — — — — —
C64–C66 Kidney 3199 4790 50 12 38 1967 2955 50 26 24
C67 Bladder
f 6394 9547 49 0 49 2582 3266 26 0 26
C71 Brain 2033 2414 19  8 26 1501 1448  4  23 19
C81 Hodgkin’s
lymphoma
690 939 36 22 14 497 636 28 18 10
C82–C85 NHL 4237 6748 59 24 36 3681 5757 56 33 23
C88, C90 Myeloma 1701 2954 74 28 46 1480 2006 36 10 26
C91–C95 Leukaemia 3084 4687 52 12 40 2409 3080 28 5 22
Other sites 13493 16470 22  21 43 12956 15107 17  82 4
C00–C97
(excluding
C44)
All excluding
NMSC
g
111639 152381 36  7 43 112477 146500 30 7 23
NHL¼non-Hodgkin’s lymphoma; NMSC¼non-melanoma skin cancer.
aAverage annual incidence as recorded 1999–2003.
bAverage annual incidence as predicted 2019–2023.
c% change in the number of new cases predicted for
2019–2023 compared to 1999–2003.
d% change in the number of new cases due to changes in risk.
e% change in the number of new cases due to changes in population age structure and size.
fIncidence rates were assumed to
remain constant for prostate and bladder cancer.
gAll cancers excluding non-melanoma cancers of skin; numbers and proportional changes based on combining the specific cancer sites.
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Epidemiologyprofessional consensus about best practice, official guidelines and
innovations in diagnostics and therapy will lead to significantly
increasing intensity and costs of care for the individual patient and
for society as a whole.
We should emphasise that the predicted rates and numbers of
cases are uncertain and depend on an assumption about the
continuity of past trends. In the analysis of the earlier predictions
in the Nordic countries (Møller et al, 2003), the errors of predicted
numbers compared with actual numbers observed subsequently
were typically 10–20% on either side. A similar analysis in
Scotland showed that half of the predicted future numbers were
incorrect by more than 10% and a fifth by more than 20% (Scottish
Executive, 2004). We have compared the present results with
corresponding estimates from a simpler method of linear
extrapolation of age-specific rates that was made available by Dyba
and Hakulinen (ENCR, 2006). Our method gave marginally
higher estimates of future numbers of cancer cases, probably
because it relies more on the cohort component (current rates in
the youngest age groups) and less on the linear extrapolation of
rates in all age groups (data not shown).
We think these predictions are the most plausible at present, but
those for individual sites will probably deviate from the actual
rates in the 2020s, to the order of 10–20% to either side, and for a
few cancers it will be larger than that. For all cancers combined, the
error should be lower because too high and too low predictions for
particular sites will tend to cancel out, but margins of error of 5%
in the rates and 10% in the numbers of cases would seem likely.
Population forecasting is required for accurate estimates of the
future events from projected rates. However, forecasted population
data are, by their nature, predictions themselves, based on
forecasted birth and death rates and immigration and emigration
levels.
Our estimates are intentionally presented without standard
errors or confidence intervals, as these would be extremely low
because of the large size of the population. The uncertainty
associated with these predictions does not concern sampling error
but the unquantifiable bias when trends in some cancers behave in
a manner that is inconsistent with the assumptions of the
statistical analysis of past rates.
The single most critical aspect of these predictions concerns the
future rates and numbers of prostate cancer. The standard set of
assumptions would predict a doubling of the age-standardised
incidence of prostate cancer, which we consider unlikely, and we
decided simply to assume that the age-specific rates in 1999–2003
would remain constant, so that future numbers of prostate cancer
would increase only in consequence of demographic changes in the
population. Recent trends in prostate cancer in England are
complex, with increases in the relatively young age groups (up to
69 years) due principally to increasing use of the prostate-specific
antigen (PSA) test. However, rates have so far declined or
remained constant in the older age groups because of increasing
medical treatment for benign urinary obstruction and resulting
decrease in use of transurethral resection, which had previously
led to many prostate cancer diagnoses (Evans and Møller, 2003):
the future use of the PSA test will be critical. If it stabilises at the
current level, our estimates will be correct or even a little high, but
if PSA testing in asymptomatic older men increases, the prostate
cancer rates and numbers may increase above our predictions.
To illustrate the sensitivity of our predictions, we assumed that
age-specific rates increased by 50% in all age groups, resulting in
the age-standardised rate of all male cancers combined increasing
by 6% (not 4%), future numbers of prostate cancer by 123% (not
48%) and future numbers of all male cancers combined by 53%
(not 36%).
We assumed that future bladder cancer rates would remain
constant. With changes in classification of bladder neoplasms, a
marked recent decrease in bladder cancer incidence is evident
(Figure 1). Previously, many in situ lesions were counted as
invasive bladder cancer. Available data did not permit a proper
reclassification to a uniform concept of bladder cancer. Rather
than allowing this artefact to predict a strong decrease, we decided
to compel the rates to remain constant. The implications of this
assumption about bladder cancer are less marked than was the
case for prostate cancer.
In summary, the present study highlights the need for early
reassessment of resources and infrastructure for cancer control
and care, in order to anticipate the increasing number of cancer
patients.
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